Fann et al identified risk factors for delirium in patients undergong myeloablative hematopoietic stem cell transplants. These can help to identify a patient who may benefit from closer monitoring and early interventions for delirium. The authors are from the University of Washington in Seattle, the Ohio State University and Arizon Medical Psychology (Scottsdale).